Genmab has raised gross proceeds of DKK 998 million ($183 million) following pricing of its previously announced private placement financing.
Genmab will issue 4,600,000 new shares with a nominal value of DKK 1 each at a price of DKK 217 per share.
Potential uses for the net proceeds from the transaction may include, among other things, and without limiting Genmab's discretion, the funding of:
Clinical development of HuMax-TF-ADC (currently in a Phase I study in eight solid tumors) and Progressing Genmab’s pipeline of pre-clinical projects towards clinical development.
View the full article at Genmab website.
For further financing deal information visit Current Agreements (subscription required)
Read: more on financing deals in pharma, biotech, life science partnering deal news, insights and glossary
View: Current Partnering’s Financing Scorecard – view top life science financing deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity